Cannabis

Brokers Offer Predictions for Aurora Cannabis Inc.’s Q2 2024 Earnings (TSE:ACB)

Aurora Cannabis Inc. (TSE:ACB – Get Rating) – Research analysts at Atb Cap Markets boosted their Q2 2024 earnings per share estimates for Aurora Cannabis in a research note issued to investors on Wednesday, June 14th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings per share of ($0.05) for the quarter, up from their previous estimate of ($0.06). The consensus estimate for Aurora Cannabis’ current full-year earnings is ($0.22) per share. Atb Cap Markets also issued estimates for Aurora Cannabis’ Q4 2024 earnings at ($0.03) EPS, FY2024 earnings at ($0.18) EPS and FY2025 earnings at ($0.12) EPS.

Aurora Cannabis (TSE:ACB – Get Rating) last announced its quarterly earnings data on Wednesday, June 14th. The company reported C($0.19) EPS for the quarter, missing analysts’ consensus estimates of C($0.05) by C($0.14). The firm had revenue of C$64.03 million during the quarter, compared to analyst estimates of C$64.18 million.

Other equities research analysts also recently issued research reports about the company. ATB Capital lowered their price objective on Aurora Cannabis from C$1.80 to C$1.50 in a research report on Thursday. CIBC lowered their price objective on Aurora Cannabis from C$1.75 to C$1.00 in a research report on Friday. Jefferies Financial Group lowered their price objective on Aurora Cannabis from C$1.80 to C$1.31 in a research report on Tuesday, February 28th. TD Securities lowered their price target on Aurora Cannabis from C$1.30 to C$1.00 in a research report on Friday. Finally, Canaccord Genuity Group lowered their price target on Aurora Cannabis from C$1.50 to C$0.80 in a research report on Thursday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Aurora Cannabis presently has an average rating of “Hold” and an average target price of C$1.65.

Aurora Cannabis Price Performance

Shares of TSE:ACB opened at C$0.70 on Monday. The company has a market cap of C$238.69 million, a P/E ratio of -0.08 and a beta of 3.00. The company has a quick ratio of 2.48, a current ratio of 4.08 and a debt-to-equity ratio of 38.00. Aurora Cannabis has a 52 week low of C$0.66 and a 52 week high of C$2.49. The business has a fifty day simple moving average of C$0.79 and a 200-day simple moving average of C$1.08.

About Aurora Cannabis

(Get Rating)

Aurora Cannabis Inc, together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada.

Featured Stories

Earnings History and Estimates for Aurora Cannabis (TSE:ACB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Aurora Cannabis, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aurora Cannabis wasn’t on the list.

While Aurora Cannabis currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.

Get This Free Report20 Stocks to Sell Now Cover

No Byline Policy

Editorial Guidelines

Corrections Policy

Source

Leave a Reply